With the introduction of direct-acting antivirals (DAAs) in Australia in 2016, most people with chronic hepatitis C can be cured of this infection. GPs and suitably qualified nurse practitioners working in all areas of primary care have a key role in identifying, testing and treating their patients with hepatitis C. The previous article in this series discussed how to identify your patients with hepatitis C. This article provides practical advice on assessing a patient after diagnosis in preparation for DAA therapy. This includes determining whether they can be safely treated in general practice or require specialist referral
Hepatitis C virus (HCV) infection is a key cause of liver disease but can be cured in more than 95% ...
Background: Direct Acting Antiviral (DAAs) drugs have a much lower burden of treatment and monitorin...
Objectives: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) has excellent cure rat...
This article is distributed under the terms of the Creative Commons Attribution 4.0 International Li...
The recent implementation of a scheme to provide universal access to direct-acting antiviral (DAA) m...
© 2016 Richmond et al. Background: Hepatitis C is a blood-borne virus primarily spread through shari...
Globally, some 71 million people are chronically infected with hepatitis C virus (HCV). Marginalized...
Background: To achieve the World Health Organization hepatitis C virus (HCV) elimination targets, it...
BACKGROUND: Hepatitis C elimination will require widespread access to treatment and responses at the...
To increase access to treatment, the Australian government enabled general practitioners (GPs) to pr...
The availability of new antiviral agents opens the way for increasing GP involvement in the manageme...
Hepatitis C virus (HCV) is a major cause of liver morbidity and mortality worldwide with increasing ...
Little is known about engagement and retention in care of people diagnosed with chronic hepatitis C ...
Hepatitis C virus (HCV) infection is a key cause of liver disease but can be cured in more than 95% ...
Background: Direct Acting Antiviral (DAAs) drugs have a much lower burden of treatment and monitorin...
Objectives: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) has excellent cure rat...
This article is distributed under the terms of the Creative Commons Attribution 4.0 International Li...
The recent implementation of a scheme to provide universal access to direct-acting antiviral (DAA) m...
© 2016 Richmond et al. Background: Hepatitis C is a blood-borne virus primarily spread through shari...
Globally, some 71 million people are chronically infected with hepatitis C virus (HCV). Marginalized...
Background: To achieve the World Health Organization hepatitis C virus (HCV) elimination targets, it...
BACKGROUND: Hepatitis C elimination will require widespread access to treatment and responses at the...
To increase access to treatment, the Australian government enabled general practitioners (GPs) to pr...
The availability of new antiviral agents opens the way for increasing GP involvement in the manageme...
Hepatitis C virus (HCV) is a major cause of liver morbidity and mortality worldwide with increasing ...
Little is known about engagement and retention in care of people diagnosed with chronic hepatitis C ...
Hepatitis C virus (HCV) infection is a key cause of liver disease but can be cured in more than 95% ...
Background: Direct Acting Antiviral (DAAs) drugs have a much lower burden of treatment and monitorin...
Objectives: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) has excellent cure rat...